Posted on 10/11/2008 in Pharmaceutical Company Product News AstraZeneca have announced that Crestor (rosuvastatin calcium) 20 mg has been found to reduce major cardiovascular (CV) events, following research.
The Jupiter (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) study's results found that patients taking the item saw a drop of 44 per cent, compared to a placebo, among men and women with elevated hsCRP and low to normal cholesterol levels.
Other results from the research found that the risk of heart attack was reduced by over half (54 per cent), with the risk of stroke cut by 48 per cent and total mortality lowered by a fifth (20 per cent).
Chief medical officer for AstraZeneca, Howard Hutchinson, said: "These results provide new information about Crestor's effects on CV risk."
He added: "The Jupiter trial confirmed that Crestor dramatically reduces LDL-C cholesterol levels and has now demonstrated a nearly 50 per cent reduction in the risk of heart attack and stroke."
The study saw a randomised, placebo-controlled, double-blind and long-term study of 17,802 patients, of which the majority had at least one other risk factor including hypertension, low HDL-C, smoking or a family history of premature coronary heart disease.Other news stories from 10/11/2008
Read more in the Zenopa News Archive
How this news is generated
|
